Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (308 reviews)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

308 publications

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 308 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Nat Genet, 2020, 10.1038/s41588-020-00729-3

PubMed: 33139953 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(11):e12525

PubMed: 33026191 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

Elife, 2020, 9e59780

PubMed: 33074102 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

J Mol Cell Cardiol, 2020, 149:73-81

PubMed: 32971072 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:573820

PubMed: 33195208 ( click the link to review the publication )

Cell Biol Toxicol, 2020, 10.1007/s10565-020-09560-2

PubMed: 33040242 ( click the link to review the publication )
Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.202048566

PubMed: 32644192 ( click the link to review the publication )

Mol Psychiatry, 2020, 10.1038/s41380-020-00958-2

PubMed: 33235333 ( click the link to review the publication )

PLoS Biol, 2020, 18(11):e3000981

PubMed: 33253182 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )
Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )
J Mol Endocrinol, 2019, 62(2):67-78

PubMed: 30481159 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )
Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )
Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)E3539

PubMed: 30424007 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

JCI Insight, 2018, 3(4)95824

PubMed: 29467324 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Elife, 2017, 6e22767

PubMed: 28318487 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )
Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )
Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

J Cell Mol Med, 2016, 20(12):2289-2298

PubMed: 27420561 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Blood, 2015, 5;125(6):941-8

PubMed: 25468569 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )
Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )
Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )
Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )
Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	NVXLUJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrKWZZCUUN3ME2wMlA3OSEQvF2=	MXrTRW5ITVJ?
ALL-PO	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\6flVKSzVyPUCuNFY{PTVizszN	M3HG[nNCVkeHUh?=
697	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPDW4I3UUN3ME2wMlA6QTd4IN88US=>	M1jLeXNCVkeHUh?=
NCI-H748	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HydGlEPTB;MD6xNFM{PCEQvF2=	MlXCV2FPT0WU
NKM-1	Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWiwc2xpUUN3ME2wMlExQTF{IN88US=>	NXjrR2hQW0GQR1XS
ES1	M{iwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDPTWM2OD1yLkGxNlU2KM7:TR?=	MVLTRW5ITVJ?
NCI-H1963	NHLNXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP3b\|ZKSzVyPUCuNVE2PzlizszN	NHjXOppUSU6JRWK=
NCI-H1417	NGTYS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoGzTWM2OD1yLkGyPVc1KM7:TR?=	M{jRS3NCVkeHUh?=
NEC8	M4jGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zNW2lEPTB;MD6xN\|UzPyEQvF2=	MVPTRW5ITVJ?
CRO-AP2	NH\DOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMU[4PFkh\|ryP	NEDx[ZNUSU6JRWK=
A3-KAW	NF20TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq4bmVKSzVyPUCuNVc3OjdizszN	NHT0VJZUSU6JRWK=
SF539	M2TqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMUm1PVMh\|ryP	MX7TRW5ITVJ?
NOS-1	M364Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33VfWlEPTB;MD6xPVYyQSEQvF2=	M4XZSXNCVkeHUh?=
NTERA-S-cl-D1	MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMkCxNVMh\|ryP	M1XwPXNCVkeHUh?=
COR-L88	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHicGN7UUN3ME2wMlIzQTV7IN88US=>	MUDTRW5ITVJ?
EM-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMkSwO\|kh\|ryP	MofDV2FPT0WU
KARPAS-45	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDMRYZKSzVyPUCuNlc5OzNizszN	MmjNV2FPT0WU
DSH1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:yT2lEPTB;MD6yPFcxQCEQvF2=	MlvoV2FPT0WU
HT-144	NHS3Z5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TlVmlEPTB;MD6zNFI2PiEQvF2=	MVfTRW5ITVJ?
ATN-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe3W45KSzVyPUCuN\|A2PzZizszN	NWfJR4Z3W0GQR1XS
HEL	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{n0Z2lEPTB;MD6zNVM1QCEQvF2=	M4LBOXNCVkeHUh?=
NB12	M3vTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDKeY5DUUN3ME2wMlMyPzV4IN88US=>	MmnyV2FPT0WU
LU-139	M{G2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2mySGlEPTB;MD6zN\|UyKM7:TR?=	Ml7UV2FPT0WU
J-RT3-T3-5	M{Twfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX:1VpFTUUN3ME2wMlM{PzF4IN88US=>	MY\TRW5ITVJ?
MOLT-13	M{PXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwM{O4NUDPxE1?	MWTTRW5ITVJ?
SR	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q4UWlEPTB;MD6zOFI3OSEQvF2=	NH;FemNUSU6JRWK=
CMK	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1j5d2lEPTB;MD6zOVczPyEQvF2=	M2TafXNCVkeHUh?=
ES8	NIH1b\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwM{[wNlIh\|ryP	MWXTRW5ITVJ?
LB647-SCLC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HjfWlEPTB;MD6zOlc{KM7:TR?=	NFz0SWtUSU6JRWK=
TE-8	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwM{[5N\|Uh\|ryP	NIm5V25USU6JRWK=
BV-173	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe2VI5vUUN3ME2wMlM4OTJzIN88US=>	NEDPe3NUSU6JRWK=
DEL	MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf5TWM2OD1yLkO3OFg4KM7:TR?=	Mm\aV2FPT0WU
ARH-77	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLvTWM2OD1yLkO4NVk{KM7:TR?=	NX;aWG9zW0GQR1XS
NCCIT	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrJeWdKSzVyPUCuN\|g3PDlizszN	NFnR[5FUSU6JRWK=
RPMI-8402	M1m1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fvcGlEPTB;MD6zPFcxOSEQvF2=	NXvVdWJrW0GQR1XS
MONO-MAC-6	M{DzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYX6UlJZUUN3ME2wMlM5Pzd4IN88US=>	M1fVTXNCVkeHUh?=
SK-MM-2	NHTBTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{W2T2lEPTB;MD6zPVg3QCEQvF2=	NUXifow6W0GQR1XS
CHP-126	NUD2[WZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M124XmlEPTB;MD60NFI{OSEQvF2=	NIG1NoVUSU6JRWK=
A101D	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwNECzJO69VQ>?	MVjTRW5ITVJ?
SCH	NEHEVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTGTWM2OD1yLkSwN\|QzKM7:TR?=	M3yzN3NCVkeHUh?=
NMC-G1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\wSGE{UUN3ME2wMlQxOzZ5IN88US=>	MXPTRW5ITVJ?
NCI-H209	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\MTWM2OD1yLkSwOlE{KM7:TR?=	NEf0bmlUSU6JRWK=
MOLT-16	M1y4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2iwU2lEPTB;MD60NVAyPyEQvF2=	M1TueHNCVkeHUh?=
RPMI-6666	NHLaVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\IRnhKSzVyPUCuOFEyOiEQvF2=	MnLtV2FPT0WU
OPM-2	NHzFS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\2b5oyUUN3ME2wMlQyPTF\|IN88US=>	MYXTRW5ITVJ?
MRK-nu-1	M2DiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHjdHBEUUN3ME2wMlQ{OTV\|IN88US=>	MV\TRW5ITVJ?
BC-1	M2nTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjY[IJLUUN3ME2wMlQ{PDB\|IN88US=>	MVvTRW5ITVJ?
MHH-NB-11	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[xTWM2OD1yLkSzOFU{KM7:TR?=	NEjS[2JUSU6JRWK=
Ramos-2G6-4C10	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLZTWM2OD1yLkSzPFk4KM7:TR?=	MojpV2FPT0WU
LS-513	MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnK4TWM2OD1yLkS0OVAyKM7:TR?=	MXTTRW5ITVJ?
K5	NV\LT5FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3LclZoUUN3ME2wMlQ4ODJ3IN88US=>	NGK4Wo9USU6JRWK=
HOP-62	NUjHPHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUi5c\|VjUUN3ME2wMlQ5OzV6IN88US=>	NWjKVZpuW0GQR1XS
NCI-H187	NUXFcY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHjZ\|ZqUUN3ME2wMlQ6OjJ5IN88US=>	NYGxd4RlW0GQR1XS
BE-13	NHLvfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\GN4hKSzVyPUCuOFk3PjFizszN	M1zsdHNCVkeHUh?=
HC-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[5W2lEPTB;MD61NFQ4OyEQvF2=	M{KwSHNCVkeHUh?=
ACN	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDiTWM2OD1yLkWxNFI5KM7:TR?=	NFHM[nhUSU6JRWK=
HCC1599	M4XkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrsRYxFUUN3ME2wMlUyPTdizszN	MUTTRW5ITVJ?
MV-4-11	M3rFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13n[2lEPTB;MD61N\|A1OSEQvF2=	M4H2eHNCVkeHUh?=
LC-2-ad	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF30U2RKSzVyPUCuOVM3PjNizszN	NUGzOnh5W0GQR1XS
HL-60	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PFNWlEPTB;MD61OFI3OSEQvF2=	NEPTOFVUSU6JRWK=
NB17	M{izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojFTWM2OD1yLkW0N\|gh\|ryP	NF\VNGZUSU6JRWK=
TE-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwNUWzNFYh\|ryP	M4LJXHNCVkeHUh?=
NCI-H524	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwNUW0NFEh\|ryP	MlznV2FPT0WU
MZ7-mel	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTiTnNNUUN3ME2wMlU3OTB3IN88US=>	M4fhb3NCVkeHUh?=
L-363	NHmzfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwNU[2OVch\|ryP	MX7TRW5ITVJ?
BL-41	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwNU[4PFkh\|ryP	MknzV2FPT0WU
LU-134-A	NV\hc\|EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPITWM2OD1yLkW3NFc{KM7:TR?=	M4D0fHNCVkeHUh?=
SIG-M5	MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3Je5JKSzVyPUCuOVc5PDhizszN	NWfFUFZUW0GQR1XS
ONS-76	M{DEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPyV\|hKSzVyPUCuOVgzPDJizszN	NFTBTGhUSU6JRWK=
KARPAS-299	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofDTWM2OD1yLkW4OVA1KM7:TR?=	M33sfHNCVkeHUh?=
DU-4475	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLrTWM2OD1yLkW4O\|A{KM7:TR?=	NX3ofWZwW0GQR1XS
NB69	NV;hblhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfjTWM2OD1yLkW5PFI2KM7:TR?=	NFTXT5NUSU6JRWK=
MHH-PREB-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwNkC3NVkh\|ryP	NUnOS\|VYW0GQR1XS
LU-165	NFrqWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ez[WlEPTB;MD62NVgyOiEQvF2=	MlLjV2FPT0WU
LOUCY	M1u4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jCUmlEPTB;MD62N\|M3PCEQvF2=	NYHQc2t4W0GQR1XS
NCI-H526	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHvXnVMUUN3ME2wMlY{PTRzIN88US=>	MkDwV2FPT0WU
KE-37	NEnOVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vSUmlEPTB;MD62OFI4PiEQvF2=	NEe4Z45USU6JRWK=
NALM-6	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XOXWlEPTB;MD62OFg3KM7:TR?=	M3;xb3NCVkeHUh?=
CW-2	NYHMb2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Dt[WlEPTB;MD62OVc6PCEQvF2=	M3jpR3NCVkeHUh?=
SU-DHL-1	M4XzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XIc2lEPTB;MD62OVk1PyEQvF2=	NWi5SJF{W0GQR1XS
NB13	NXrjd441T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwNk[4NVch\|ryP	MnrsV2FPT0WU
QIMR-WIL	NUHpeplXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorJTWM2OD1yLk[4N\|Q{KM7:TR?=	NYe4e\|dNW0GQR1XS
ECC12	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{K5OGlEPTB;MD63NFA5PiEQvF2=	NIrGe4tUSU6JRWK=
KALS-1	M3m2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vEN2lEPTB;MD63NFQ6OiEQvF2=	MUXTRW5ITVJ?
COR-L279	M2nmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TKbGlEPTB;MD63NFk6PiEQvF2=	MnPHV2FPT0WU
NB14	NEDveVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTCTWM2OD1yLkeyOlE4KM7:TR?=	NXny[nZYW0GQR1XS
CCRF-CEM	NFrNZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT5TWM2OD1yLke0OlYyKM7:TR?=	M3ftW3NCVkeHUh?=
SW954	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwN{W5PVkh\|ryP	NGTYVnVUSU6JRWK=
IST-SL1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofSTWM2OD1yLke3N\|Q5KM7:TR?=	NGnpb4FUSU6JRWK=
LAMA-84	M{X0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUP4SpdvUUN3ME2wMlc4PTZ5IN88US=>	NH[0PJJUSU6JRWK=
Daudi	NXHUZo17T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwN{e2PFEh\|ryP	NIO5bFlUSU6JRWK=
BC-3	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nKeWlEPTB;MD63PFMxQCEQvF2=	M{ewVHNCVkeHUh?=
HCC2998	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LGdWlEPTB;MD63PFM3KM7:TR?=	MmDXV2FPT0WU
NCI-H69	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TWW2lEPTB;MD64NFE1PyEQvF2=	M2DuSXNCVkeHUh?=
CPC-N	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIC1c4lKSzVyPUCuPFA2OjRizszN	NW\2cpVTW0GQR1XS
NOMO-1	NVf2R4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwOEGwPFQh\|ryP	M3Xud3NCVkeHUh?=
CESS	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHWTWM2OD1yLkixNVk4KM7:TR?=	MXrTRW5ITVJ?
LC4-1	M4i1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwOESwNFch\|ryP	NFvlfXRUSU6JRWK=
BL-70	NWP6b2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwOEW3NFIh\|ryP	NYTWOVFOW0GQR1XS
ES4	NHHhVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XldWlEPTB;MD64OVg3QCEQvF2=	NIr1bZVUSU6JRWK=
HCE-T	NFnxXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLHSmpKSzVyPUCuPFcyPzFizszN	MmLmV2FPT0WU
JAR	M1fzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX61eW5tUUN3ME2wMlg4QDJ5IN88US=>	MlLPV2FPT0WU
ST486	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwOEe5NVch\|ryP	MoHrV2FPT0WU
KS-1	NVO1eZJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXGTWM2OD1yLki4NFk3KM7:TR?=	MkH2V2FPT0WU
GDM-1	NF\VSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDncmtKSzVyPUCuPFg3QDdizszN	M12wO3NCVkeHUh?=
EHEB	NV\yU\|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPHZllKSzVyPUCuPVI2QDVizszN	MUTTRW5ITVJ?
LB2518-MEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwOUOyPFQh\|ryP	M3PUfnNCVkeHUh?=
GOTO	NUL3b\|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwOUWwO\|Yh\|ryP	NX\oXIxOW0GQR1XS
LXF-289	NXXWUIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonDTWM2OD1yLkm1PVAyKM7:TR?=	M4HT[nNCVkeHUh?=
ES6	NHjiTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnrZ\|Z5UUN3ME2wMlk3PDN5IN88US=>	NFL3NVJUSU6JRWK=
OS-RC-2	M1fSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwOU[4N{DPxE1?	Mkn6V2FPT0WU
DMS-153	NUjv[XBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmr2TWM2OD1yLkm3OFY6KM7:TR?=	NHL4UJVUSU6JRWK=
SK-PN-DW	M1XjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfrZ5FKSzVyPUCuPVc5OzFizszN	NXrXOpZQW0GQR1XS
HH	NIDKVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHJUW1iUUN3ME2wMlk5QTV7IN88US=>	MYTTRW5ITVJ?
SH-4	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUX1WnBoUUN3ME2xMlAzPDFizszN	M{K2OnNCVkeHUh?=
MOLT-4	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPwfo1KSzVyPUGuNFM1PTRizszN	M4DYZnNCVkeHUh?=
TGW	NV6wN44zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDpNnJKSzVyPUGuNFc3PzVizszN	MVTTRW5ITVJ?
L-540	NWfndm52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnPWYNKSzVyPUGuNVA3ODRizszN	NWjR[4ZqW0GQR1XS
PF-382	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFwMUG1NVMh\|ryP	MYXTRW5ITVJ?
LC-1F	NIj3XY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LLU2lEPTB;MT6xNlAxPyEQvF2=	M{TpT3NCVkeHUh?=
OVCAR-4	NGrIbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojKTWM2OD1zLkGzNVY2KM7:TR?=	NFP3O2xUSU6JRWK=
A4-Fuk	NEnGVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[2N4VKSzVyPUGuNVU{PjRizszN	MoLLV2FPT0WU
HCC2218	NVfDfFh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTFwMU[2OFEh\|ryP	MkD2V2FPT0WU
HAL-01	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTFwMU[5OFMh\|ryP	NEDZS5dUSU6JRWK=
IST-MEL1	M4GzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PVNGlEPTB;MT6xO\|Y2QSEQvF2=	MWTTRW5ITVJ?
NCI-H719	NUK1XlZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\vTWM2OD1zLkG3PFk5KM7:TR?=	NF;nb4pUSU6JRWK=
EVSA-T	NF35TY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LSdmlEPTB;MT6xPFEyPCEQvF2=	NUT0eY1HW0GQR1XS
SK-NEP-1	NWfHeVdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTFwMkCyOlYh\|ryP	MoXiV2FPT0WU
OCUB-M	NFzPepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofnTWM2OD1zLkKxOFg6KM7:TR?=	MV7TRW5ITVJ?
MEG-01	M33OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInKfXJKSzVyPUGuNlIyOThizszN	MUPTRW5ITVJ?
no-10	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIC2fFZKSzVyPUGuNlMyOTJizszN	NHXXbopUSU6JRWK=
MHH-CALL-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3yTWM2OD1zLkK0O\|IyKM7:TR?=	NEnROVRUSU6JRWK=
SK-N-DZ	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUj4S3BRUUN3ME2xMlI1Pzd4IN88US=>	NUKze5ZXW0GQR1XS
SCLC-21H	MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTFwMk[0O\|gh\|ryP	M2qwTHNCVkeHUh?=
CTV-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrlcHpOUUN3ME2xMlI4PDJ3IN88US=>	MVHTRW5ITVJ?
NB1	NUm2dJRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTFwMke3N\|Ih\|ryP	MWXTRW5ITVJ?
NCI-H64	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnveXdKSzVyPUGuNlg1PjJizszN	MoC1V2FPT0WU
MDA-MB-134-VI	NHL1S\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLoTWM2OD1zLkK4OVc4KM7:TR?=	MX7TRW5ITVJ?
LB2241-RCC	NFfVTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDGWmRKSzVyPUGuNlg3PjNizszN	M1ToRXNCVkeHUh?=
8-MG-BA	M3nlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XqU2lEPTB;MT6yPFg3PiEQvF2=	Mk\ZV2FPT0WU
LP-1	NGTXZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTFwMkm5OFch\|ryP	NFvrSHpUSU6JRWK=
LS-411N	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFwM{C5PVgh\|ryP	NUKyc45jW0GQR1XS
CAL-148	M3jNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTFwM{K1OFIh\|ryP	MULTRW5ITVJ?
NCI-H2171	M3LkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXvU5VKSzVyPUGuN\|Q2ODJizszN	Ml\qV2FPT0WU
JiyoyeP-2003	NETXWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrC[IplUUN3ME2xMlM2OzlizszN	MXPTRW5ITVJ?
NCI-H2107	M{naOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH5[mdKSzVyPUGuN\|U5QDNizszN	NEXjRYFUSU6JRWK=
BB30-HNC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwM{i5O\|gh\|ryP	NG\6W\|FUSU6JRWK=
K-562	M{iyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVSzR3hFUUN3ME2xMlM6OjF7IN88US=>	MmXSV2FPT0WU
PSN1	NGfJ[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTFwNEKyPFch\|ryP	MXrTRW5ITVJ?
HCC2157	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln3TWM2OD1zLkSyOlkyKM7:TR?=	NFnNfnlUSU6JRWK=
SBC-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\6NmlEPTB;MT60Nlc1OSEQvF2=	NHr3RoxUSU6JRWK=
MC116	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTFwNEO2NVUh\|ryP	MVjTRW5ITVJ?
KARPAS-422	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3GzR2lEPTB;MT60OVM2QCEQvF2=	Ml62V2FPT0WU
LB996-RCC	NFu2NnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHaWJNKSzVyPUGuOFcyODNizszN	M3rue3NCVkeHUh?=
MSTO-211H	NXjrNGI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfsS5huUUN3ME2xMlQ4QTh5IN88US=>	NFL4NZNUSU6JRWK=
BT-474	MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTr[GNKSzVyPUGuOVE4PjRizszN	NVn2SIF3W0GQR1XS
A388	M3fL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVj3W4czUUN3ME2xMlUyQTR3IN88US=>	M{DJXXNCVkeHUh?=
SJSA-1	M4fhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDifoFKSzVyPUGuOVIzPiEQvF2=	MoLvV2FPT0WU
COLO-829	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWqzblJQUUN3ME2xMlU{PTZ2IN88US=>	MWTTRW5ITVJ?
KM-H2	M4nkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\2NY57UUN3ME2xMlU3PjdizszN	NWLFd\|JUW0GQR1XS
GR-ST	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUGyS4tCUUN3ME2xMlU3QDJizszN	NH7tOYZUSU6JRWK=
RPMI-8866	NYnZZ4czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwNkCxOFQh\|ryP	MUfTRW5ITVJ?
KG-1	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwNkG5NFEh\|ryP	MoL4V2FPT0WU
NCI-H82	NYjoTYFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTFwNkO0NFYh\|ryP	MYfTRW5ITVJ?
LB1047-RCC	M4C5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwNkO0OVkh\|ryP	NXvLd2JrW0GQR1XS
KM12	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTFwNkS3JO69VQ>?	MnPnV2FPT0WU
NB5	MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnwWoJKSzVyPUGuOlU3PzdizszN	M3PyNXNCVkeHUh?=
HDLM-2	NF7ZTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml25TWM2OD1zLk[4NlgyKM7:TR?=	NY\C[mlsW0GQR1XS
KU812	NIPuOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwNkm2NFUh\|ryP	MYXTRW5ITVJ?
DB	NFXSfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXtTWM2OD1zLkewN\|U{KM7:TR?=	NVXVd4lWW0GQR1XS
HD-MY-Z	M1H3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTsNWpKSzVyPUGuO\|UzOzRizszN	M{W5OHNCVkeHUh?=
KURAMOCHI	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFW1emNKSzVyPUGuO\|czODdizszN	NYHn[oZJW0GQR1XS
ETK-1	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlj1TWM2OD1zLke4PFc6KM7:TR?=	MVXTRW5ITVJ?
SK-UT-1	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTFwN{mzPFgh\|ryP	NXvqfFRVW0GQR1XS
HUTU-80	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXPPGlEUUN3ME2xMlc6PTB6IN88US=>	NF3rcIZUSU6JRWK=
ES7	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzVTWM2OD1zLkiwN\|AzKM7:TR?=	MYjTRW5ITVJ?
SW872	M1zUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHuTWM2OD1zLkixN\|k2KM7:TR?=	M2fPe3NCVkeHUh?=
TK10	NXnoWI82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPIfHNKSzVyPUGuPFMyODhizszN	MUPTRW5ITVJ?
LB831-BLC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTXPI1JUUN3ME2xMlg{PTZ\|IN88US=>	NV;VbmozW0GQR1XS
TE-9	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmiyTWM2OD1zLki0OFIzKM7:TR?=	M{nOXnNCVkeHUh?=
MLMA	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTFwOEiyN\|Qh\|ryP	NFP2eoFUSU6JRWK=
D-542MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFwOEmzO\|Mh\|ryP	M4\6[XNCVkeHUh?=
EW-16	MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnCTWM2OD1zLkmyO\|Ih\|ryP	NXnRS4xXW0GQR1XS
LOXIMVI	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFwOUOyPEDPxE1?	MoXFV2FPT0WU
GB-1	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzvZ3JxUUN3ME2xMlk{QDZ4IN88US=>	NWe0R5JYW0GQR1XS
IST-SL2	NH22cJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTJwMECyOlIh\|ryP	MUjTRW5ITVJ?
LAN-6	M{[5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vPR2lEPTB;Mj6wNVk3PiEQvF2=	MlLYV2FPT0WU
NCI-H510A	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrpbIdNUUN3ME2yMlA1PTB{IN88US=>	NGizbnpUSU6JRWK=
NCI-H1092	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnCfGtkUUN3ME2yMlA2OTJ2IN88US=>	MlyxV2FPT0WU
HT	MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXKc\|ZKSzVyPUKuNVA1PTRizszN	NVHKTYM5W0GQR1XS
RL95-2	M3jtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJwMUG0PFIh\|ryP	MnPtV2FPT0WU
NCI-H1355	M1O4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PPdmlEPTB;Mj6xNVc6OiEQvF2=	NEnqVYtUSU6JRWK=
NCI-H720	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnTXpgxUUN3ME2yMlE3QDd\|IN88US=>	NV\J[IlzW0GQR1XS
NCI-H1522	M3vxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjZcVhsUUN3ME2yMlIyPzJ\|IN88US=>	MWPTRW5ITVJ?
LB373-MEL-D	NV[wWHo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTJwMk[5NFIh\|ryP	Mn7mV2FPT0WU
DG-75	NWi0NndzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3f0dmlEPTB;Mj6yO\|E1QCEQvF2=	MXPTRW5ITVJ?
ML-2	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXE[HpYUUN3ME2yMlMzQDV3IN88US=>	NVHOXppYW0GQR1XS
SF126	NEDwNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3[5VWlEPTB;Mj6zN\|A6PCEQvF2=	NVW5eHdSW0GQR1XS
MPP-89	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\BfWIzUUN3ME2yMlM{OTR3IN88US=>	M{HFXnNCVkeHUh?=
NCI-H345	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTJwM{OyO\|ch\|ryP	NGPRdpRUSU6JRWK=
LS-123	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1u0fWlEPTB;Mj6zOFk{PiEQvF2=	NYPqOYlSW0GQR1XS
NB10	NYD0XYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnUbHVKSzVyPUKuOFExQTJizszN	MnvzV2FPT0WU
CGTH-W-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPReXhKSzVyPUKuOFIzPjdizszN	NEK5VJZUSU6JRWK=
CP66-MEL	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLhTWM2OD1{LkS3O\|ch\|ryP	NWrGWIo1W0GQR1XS
L-428	NY\Qb\|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jHN2lEPTB;Mj60PFUzOSEQvF2=	MljsV2FPT0WU
DMS-79	MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;LXnVKSzVyPUKuOVQyODNizszN	MnTVV2FPT0WU
NCI-H1882	NWLGTGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUmwXoJwUUN3ME2yMlY4PTZ{IN88US=>	M{X4NHNCVkeHUh?=
KGN	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHaOG56UUN3ME2yMlc3QDd4IN88US=>	MWfTRW5ITVJ?
EW-1	M{nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fBfmlEPTB;Mj63O\|A5OyEQvF2=	M1HYUnNCVkeHUh?=
U-266	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4G1OGlEPTB;Mj64OFgzOyEQvF2=	MWrTRW5ITVJ?
COLO-320-HSR	NHLy[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fBT2lEPTB;Mj64OVY1OSEQvF2=	MnjkV2FPT0WU
KMOE-2	M{TkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTJwOEe3NVEh\|ryP	M4HQdXNCVkeHUh?=
BB49-HNC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjBZYVKSzVyPUKuPVI1QCEQvF2=	M1TQT3NCVkeHUh?=
GI-1	NH3mTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;nTWM2OD1{LkmyPVU4KM7:TR?=	NHe3XY5USU6JRWK=
NCI-H1304	NXLiN3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DoSmlEPTB;Mz6wNFUyOSEQvF2=	NYHPeFBPW0GQR1XS
NCI-H2227	NVPyTWJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTNwMEKwO\|kh\|ryP	MYXTRW5ITVJ?
U-87-MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzjTWM2OD1\|LkCzOVE{KM7:TR?=	NHHFbm5USU6JRWK=
NCI-H747	M4rQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHYUIMyUUN3ME2zMlA2OjB4IN88US=>	M1TrbXNCVkeHUh?=
CTB-1	M4TTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrwXm83UUN3ME2zMlA2Ozd4IN88US=>	MVvTRW5ITVJ?
RPMI-8226	NF;kWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XlbGlEPTB;Mz6xOFM4QCEQvF2=	M1\Hb3NCVkeHUh?=
NCI-H2141	NVjlbId6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT6TWM2OD1\|LkG2OVY3KM7:TR?=	MVjTRW5ITVJ?
IST-MES1	NIfuW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPhTWM2OD1\|LkG4Nlc6KM7:TR?=	MXrTRW5ITVJ?
TE-5	M2[4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTNwMkGzOFIh\|ryP	NFvjVYFUSU6JRWK=
UACC-257	NYThT5hIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTNwNEO2OVkh\|ryP	NYLvS2J7W0GQR1XS
SK-N-FI	M1\jUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfETWM2OD1\|LkS1NlI4KM7:TR?=	MUfTRW5ITVJ?
MFH-ino	NGHIUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkGxTWM2OD1\|LkS2OVg6KM7:TR?=	NXH1NGJ2W0GQR1XS
SF268	M2jGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nHcWlEPTB;Mz60PFE4PCEQvF2=	M4TnPXNCVkeHUh?=
TE-12	Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUW5WJFxUUN3ME2zMlUyPjl7IN88US=>	MmLpV2FPT0WU
NB6	M4DLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTPTnZ[UUN3ME2zMlU2PTZ\|IN88US=>	MYPTRW5ITVJ?
DJM-1	M2jXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17ZNWlEPTB;Mz61PVg6QSEQvF2=	NX3FVXFNW0GQR1XS
MZ1-PC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkD0TWM2OD1\|Lk[xOlI1KM7:TR?=	M3viSHNCVkeHUh?=
OCI-AML2	NHHoWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXITWM2OD1\|Lk[yOlcyKM7:TR?=	MYjTRW5ITVJ?
NCI-H1155	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\0TWM2OD1\|LkewPVQ4KM7:TR?=	MV3TRW5ITVJ?
RKO	NHS2TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PLOGlEPTB;Mz63O\|E5QSEQvF2=	MnTMV2FPT0WU
ECC4	NGHIT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXntOXpnUUN3ME2zMlk4OTl3IN88US=>	NV[0dm92W0GQR1XS
BB65-RCC	NHKxWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDlUolVUUN3ME2zMlk4PTR5IN88US=>	MYPTRW5ITVJ?
EB-3	NXflV5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELOZYRKSzVyPUOuPVk3OzNizszN	NWDT[G5zW0GQR1XS
SHP-77	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\ERmVKSzVyPUSuNFA2OjRizszN	MXvTRW5ITVJ?
NCI-H2196	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHJTWM2OD12LkC1OlI2KM7:TR?=	M3XsRXNCVkeHUh?=
GI-ME-N	NGfSVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3TUldKSzVyPUSuNFY{QTlizszN	NVKzV403W0GQR1XS
MN-60	NV;RUZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTRwMUC4O{DPxE1?	M{\T[HNCVkeHUh?=
NCI-H1694	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPDPHlRUUN3ME20MlE{PDB3IN88US=>	MYjTRW5ITVJ?
LU-65	M3TGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTRwMUWzN\|Ih\|ryP	NVu0TYJLW0GQR1XS
NCI-H1436	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3JTWM2OD12LkG4N\|M{KM7:TR?=	NEL5[XdUSU6JRWK=
KINGS-1	NYryTVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHDRm9KSzVyPUSuN\|E1OzJizszN	NEXQW5FUSU6JRWK=
GT3TKB	M4fJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PlTmlEPTB;ND6zN\|I3QCEQvF2=	NGPscmRUSU6JRWK=
Becker	M2njVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XYeWlEPTB;ND6zO\|MyOiEQvF2=	MnPIV2FPT0WU
HCC1187	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3KzdGlEPTB;ND64PVY2PyEQvF2=	NVm0PIg1W0GQR1XS
D-502MG	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTVwMEC0NVYh\|ryP	M3vZUXNCVkeHUh?=
VA-ES-BJ	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTZOWNtUUN3ME21MlE{Pzd6IN88US=>	M1XLVXNCVkeHUh?=
NB7	NIDUWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mme2TWM2OD13LkG0NVEzKM7:TR?=	MWjTRW5ITVJ?
SW962	NEe3SJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTVwM{i4NVQh\|ryP	MYHTRW5ITVJ?
no-11	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTVwN{[zOFMh\|ryP	MlX1V2FPT0WU
KNS-81-FD	M2XsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zzb2lEPTB;NT65NFY6PCEQvF2=	MlnaV2FPT0WU
COLO-684	NVHCW4w4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTkXlBKSzVyPUWuPVk1QTRizszN	MVfTRW5ITVJ?
D-263MG	NXTQS4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTZwMEi4PVUh\|ryP	NV\MTYZDW0GQR1XS
EW-24	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXxOZZxUUN3ME22MlI5PTFizszN	NVzEbndJW0GQR1XS
TE-10	NFvlSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPrTWM2OD14LkSyOlI{KM7:TR?=	NXLJZVBIW0GQR1XS
EKVX	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XoR2lEPTB;Nj60OlMzOSEQvF2=	M2roXnNCVkeHUh?=
NCI-H1648	M2i2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzhTWRKSzVyPU[uOlc2PTdizszN	NYTNSoljW0GQR1XS
LB771-HNC	M{jnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlX3TWM2OD14LkmyN\|AyKM7:TR?=	NXvZ[mZ2W0GQR1XS
SK-MEL-1	NIPOZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIOxT3RKSzVyPUiuNVMyPjZizszN	MUfTRW5ITVJ?
COLO-668	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRThwMke3PFYh\|ryP	NF7HSmNUSU6JRWK=
EW-12	NIjhbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHoZ\|RGUUN3ME24MlQxQDB\|IN88US=>	M1rhfnNCVkeHUh?=
A253	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUKwdFRuUUN3ME24Mlg1PjZzIN88US=>	NEe1UlVUSU6JRWK=
NCI-H2126	NHLBWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXJdZlxUUN3ME24Mlg6OzF7IN88US=>	NX3HOnRYW0GQR1XS
Calu-6	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRThwOUmwOFIh\|ryP	NGfTepdUSU6JRWK=
NCI-H23	NUP4TIJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnGdllKSzVyPUmuNVc4PDZizszN	NH3wPJJUSU6JRWK=
WSU-NHL	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXr3SYJ4UUN3ME25Mlc4PDd6IN88US=>	NXPQcJJQW0GQR1XS
MMAC-SF	NYTDUFJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zqUWlEPTB;OT65O\|kxPCEQvF2=	MoO3V2FPT0WU
SK-LMS-1	M17mdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO4dY9KSzVyPUGwMlI5OzRizszN	NGX1[4VUSU6JRWK=
GCIY	M{jLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS1TWM2OD1zMD61PVI1KM7:TR?=	M3zLUHNCVkeHUh?=
TE-15	NH;KNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\CfVZKSzVyPUGxMlYxODRizszN	NHPXWFhUSU6JRWK=
EoL-1-cell	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXCcGJDUUN3ME2xNU44Pjh{IN88US=>	NWPXUHVmW0GQR1XS
NCI-H2081	M3O0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTFzLke3PFYh\|ryP	NYDNe4xTW0GQR1XS
EW-3	M{XFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHjTWM2OD1zMj6yOFY{KM7:TR?=	NWPJVm9xW0GQR1XS
CAS-1	NXvydnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWS1b5pXUUN3ME2xNk4{PjNzIN88US=>	NHnxXXBUSU6JRWK=
C2BBe1	NGXPPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfqTI9KSzVyPUGyMlYyOzFizszN	MlzGV2FPT0WU
D-247MG	M37Hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PGeGlEPTB;MUKuO\|k2OiEQvF2=	MkLXV2FPT0WU
NCI-SNU-5	NH7XbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPDTWM2OD1zMj64NFE{KM7:TR?=	NHTBb3RUSU6JRWK=
LS-1034	NYrUV\|lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTF2LkO5O\|Uh\|ryP	M{Due3NCVkeHUh?=
EW-18	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTF2LkS0PEDPxE1?	MkPTV2FPT0WU
Raji	M{nNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTF2LkWwOFkh\|ryP	Ml\HV2FPT0WU
D-283MED	M3HHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnxbWFKSzVyPUG0MlYzPzFizszN	NWixW\|k6W0GQR1XS
MZ2-MEL	NU[5Z4NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHW3eodKSzVyPUG0Mlk3QTZizszN	MVvTRW5ITVJ?
NCI-SNU-16	NVzvXWpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{G0UWlEPTB;MUWuOFY{OyEQvF2=	NVP0[YhQW0GQR1XS
P30-OHK	NYHwWHUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFX6W\|lKSzVyPUG3Mlc5OzFizszN	Mn;TV2FPT0WU
RXF393	M1LKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[yRotKSzVyPUG5MlAyQDZizszN	M1LIUHNCVkeHUh?=
NCI-H1395	NEfXdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET3fGdKSzVyPUKwMlY4ODNizszN	MXHTRW5ITVJ?
U-698-M	M4DZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7kTWM2OD1{MD63NFc2KM7:TR?=	MWHTRW5ITVJ?
NCI-SNU-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz1c\|JKSzVyPUKwMlczOjNizszN	NV:zRWJ6W0GQR1XS
SW684	NIPrSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTsbGpGUUN3ME2yNU4yPzF4IN88US=>	MUDTRW5ITVJ?
NCI-H716	NHjKTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7YVFNKSzVyPUKxMlMyPTRizszN	MYfTRW5ITVJ?
JVM-2	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\vRmlEPTB;MkGuOFE{OyEQvF2=	MXLTRW5ITVJ?
NCI-H1581	NVKxT25ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUewbG05UUN3ME2yNk41OTR6IN88US=>	NEiwdVJUSU6JRWK=
CA46	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrzUZZKSzVyPUOxMlY6OzZizszN	MVPTRW5ITVJ?
SNB75	M2DqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7hdJgzUUN3ME2zN{43PTB\|IN88US=>	Ml34V2FPT0WU
KNS-42	NF;Tc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTN3Lkm2NlQh\|ryP	NGDNOVdUSU6JRWK=
TUR	NV\3cnhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LBTGlEPTB;M{[uNFUzOSEQvF2=	NEDxRWxUSU6JRWK=
REH	NELPVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\I[WlEPTB;M{euPFIyOSEQvF2=	M{fpRnNCVkeHUh?=
EW-22	NUPB[XFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTR{LkK4PFUh\|ryP	M{fjWHNCVkeHUh?=
NCI-H446	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvxNndMUUN3ME20Nk44QDV\|IN88US=>	M{XGOHNCVkeHUh?=
ES3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTR\|LkGzN\|kh\|ryP	NYnlNnJOW0GQR1XS
EW-11	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M332RmlEPTB;NESuPFIyQCEQvF2=	MUnTRW5ITVJ?
RH-1	NEj2T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTR5LkW4NVIh\|ryP	MnzwV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SNDX-275
Smiles	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Active not recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)